IIT Madras Releases Cancer Genome Database to Strengthen India-Specific Research
On February 4, 2026, the Indian Institute of Technology Madras (IIT Madras) announced the launch of a groundbreaking cancer genome database aimed at enhancing research specific to the Indian population. This initiative is particularly significant given the rising incidence of cancer in India, which has seen an annual increase of 12.8% since 2022.
Overview of the Bharat Cancer Genome Atlas (BCGA)
The newly released Bharat Cancer Genome Atlas (BCGA) focuses on three major types of cancer: paediatric leukaemia, colorectal cancer, and pancreatic cancer. The database is publicly accessible to researchers and clinicians both in India and internationally via the website bcga.iitm.ac.in.
Importance of Cancer Research in India
According to a report by the Indian Council of Medical Research, one in nine Indians is likely to develop cancer, with approximately 2.5 million people currently living with the disease. Despite this alarming statistic, Indian patients have been under-represented in global cancer genome studies, which has hindered the development of effective, population-specific treatment strategies.
Background of the Initiative
To address this gap, IIT Madras initiated the Indian Cancer Genome Programme in 2020. This program has successfully completed whole genome sequencing of patient samples collected from across the country. The project received principal support from Hyundai Motor India’s Hyundai Hope for Cancer initiative, which provided ₹56 crore in funding, along with an additional ₹3 crore to support treatment for economically disadvantaged families.
Collaborative Efforts
The research was led by the Centre of Excellence on Cancer Genomics and Molecular Therapeutics at IIT Madras, in collaboration with Karkinos Healthcare in Mumbai and several hospitals in Chennai. This collaborative approach has been essential in gathering diverse data that reflects the genetic variations present in the Indian population.
Additional Resources: Bharat Cancer Genome Grid (BCG2)
In conjunction with the BCGA, IIT Madras also launched the Bharat Cancer Genome Grid (BCG2). This clinician-centric platform is designed to integrate genomic data into routine oncology practice, facilitating improved patient care and treatment outcomes.
Support and Outreach Initiatives
The initiative is supported by the Department of Science and Technology as well as the National Center for Precision Medicine in Cancer. It encompasses various outreach programs, including:
- Screening camps to identify cancer at early stages.
- Training programs for technicians to enhance their skills in genomic research.
- Mobile healthcare outreach to provide services to underserved communities.
Future Implications
The establishment of the BCGA and BCG2 is expected to significantly impact cancer research and treatment in India. By providing a comprehensive database of cancer genomes, researchers will be able to:
- Identify biomarkers that can lead to early diagnosis of various cancers.
- Monitor disease progression more effectively.
- Guide population-specific treatment plans that take into account the unique genetic makeup of Indian patients.
Conclusion
The release of the Bharat Cancer Genome Atlas marks a significant step forward in cancer research in India. By focusing on the unique genetic characteristics of the Indian population, this initiative aims to improve treatment outcomes and enhance the overall understanding of cancer within the country. The collaborative efforts between IIT Madras, healthcare providers, and governmental support highlight the importance of integrating research with clinical practice to combat the growing cancer crisis in India.
Note: The information presented in this article is based on the latest developments as of February 2026. For ongoing updates, please refer to credible sources and research publications.
